Novasep is investing $38.8 million to build a new plant at its Mourenx, France site to produce large volume commercial API. According to the company, the plant will be operational and validated within 18 months. The new plant will include Varicol systems with 1,200 mm diameter columns operated at up to 70 bars and will enable the production of a highly purified API from a complex mixture. The systems will also integrate solvent recovery systems for the recycling of 99.9% of solvents, according to the company.
This investment follows the opening of a new 2,000m2 facility in Shanghai, China and a $3.9 million investment to expand Highly Potent API (HPAPI) manufacturing capabilities at its facility in Le Mans, France.
"Demand for Novasep's advanced, purification-based manufacturing capabilities in the life science industries continues to increase as drugs in development and reaching the market become more complex and specific. This necessitates our third, and largest global plant expansion in 2012," said Patrick Glaser, president and chief executive officer of Novasep. "This successful project, the world's largest chromatography plant in the pharmaceutical industry, demonstrates the validity of the Novasep strategy which is based on the combination of synthesis, biosynthesis and purification. We thank our institutional partners for their active support and our shareholders for their strong involvement to enable this transforming project."